| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
126,620,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.3637 - $0.3637 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Diagnostic Substances |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Atossa Therapeutics is a clinical-stage biopharmaceutical company seeking to discover and develop medicines in areas of oncology and infectious diseases, with a focus on breast cancer, other breast conditions and COVID-19. Co.'s drug under development for breast cancer and other breast conditions is Endoxifen which is being developed primarily in two settings. Co.'s two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
25,000 |
25,000 |
25,000 |
25,000 |
| Total Buy Value |
$44,250 |
$44,250 |
$44,250 |
$44,250 |
| Total People Bought |
1 |
1 |
1 |
1 |
| Total Buy Transactions |
1 |
1 |
1 |
1 |
| Total Shares Sold |
0 |
50,000 |
50,000 |
50,000 |
| Total Sell Value |
$0 |
$32,500 |
$32,500 |
$32,500 |
| Total People Sold |
0 |
1 |
1 |
1 |
| Total Sell Transactions |
0 |
1 |
1 |
1 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Finn Jonathan |
|
– • – |
2024-04-10 |
4 |
B |
$1.77 |
$44,250 |
D/D |
25,000 |
25,000 |
0.01 |
- |
|
| Weaver Gregory L |
Former EVP, CFO, & Director |
• • – |
2023-11-15 |
4 |
S |
$0.65 |
$32,500 |
D/D |
(50,000) |
55 |
|
- |
|
| Weaver Gregory L |
Director |
• • – |
2021-07-02 |
4 |
S |
$5.58 |
$599,833 |
D/D |
(107,497) |
0 |
|
- |
|
| Weaver Gregory L |
Director |
• • – |
2021-07-02 |
4 |
D |
$6.40 |
$365,338 |
D/D |
(57,084) |
107,497 |
|
- |
|
| Weaver Gregory L |
Director |
• • – |
2021-07-02 |
4 |
OE |
$1.70 |
$365,337 |
D/D |
164,581 |
164,581 |
|
- |
|
| Guse Kyle |
CFO, Gen Counsel and Secretary |
• – – |
2017-11-15 |
4 |
B |
$0.34 |
$3,369 |
D/D |
10,000 |
10,000 |
2.66 |
- |
|
| Remmel H. Lawrence |
Director |
– • – |
2017-04-17 |
4 |
B |
$0.63 |
$1,580 |
D/D |
2,500 |
3,126 |
2.31 |
- |
|
| Remmel H. Lawrence |
Director |
– • – |
2016-04-01 |
4 |
B |
$0.33 |
$495 |
D/D |
1,500 |
10,900 |
2.31 |
- |
|
| Chen Shu-Chih |
Director |
– • • |
2016-03-09 |
4 |
B |
$0.37 |
$5,550 |
I/I |
15,000 |
4,348,315 |
2.17 |
- |
|
| Quay Steven C |
President & CEO |
• • • |
2016-03-09 |
4 |
B |
$0.37 |
$5,550 |
I/I |
15,000 |
4,826,858 |
2.56 |
- |
|
| Quay Steven C |
President & CEO |
• • • |
2016-02-16 |
4 |
B |
$0.53 |
$7,950 |
I/I |
15,000 |
4,811,858 |
2.56 |
- |
|
| Chen Shu-Chih |
Director |
– • • |
2016-02-16 |
4 |
B |
$0.53 |
$7,950 |
I/I |
15,000 |
4,333,315 |
2.17 |
- |
|
| Chen Shu-Chih |
Director |
– • • |
2016-01-19 |
4 |
B |
$0.20 |
$10,000 |
I/I |
50,000 |
4,318,315 |
2.17 |
- |
|
| Quay Steven C |
President & CEO |
• • • |
2016-01-19 |
4 |
B |
$0.20 |
$10,000 |
I/I |
50,000 |
4,796,858 |
2.56 |
- |
|
| Remmel H. Lawrence |
Director |
– • – |
2015-06-12 |
4 |
B |
$1.30 |
$7,020 |
D/D |
5,400 |
9,400 |
2.39 |
- |
|
| Destro Christopher S. |
Sr. VP, Sales and MarketingOff |
• – – |
2014-05-06 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
100 |
|
- |
|
| Weaver Gregory L |
Director |
– • – |
2014-05-06 |
4 |
D |
$0.00 |
$0 |
D/D |
(24,510) |
0 |
|
- |
|
| Steinhart Richard I |
Director |
– • – |
2014-05-06 |
4 |
D |
$0.00 |
$0 |
D/D |
(22,728) |
0 |
|
- |
|
| Steinhart Richard I |
Director |
– • – |
2014-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
22,728 |
22,728 |
|
- |
|
| Weaver Gregory L |
Director |
– • – |
2013-11-21 |
4 |
B |
$2.58 |
$25,785 |
D/D |
10,000 |
34,510 |
2.39 |
- |
|
| Weaver Gregory L |
Director |
– • – |
2013-10-10 |
4 |
A |
$0.00 |
$0 |
D/D |
24,510 |
24,510 |
|
- |
|
| Quay Steven C |
CEO |
• • • |
2013-10-01 |
4 |
AS |
$5.66 |
$41,105 |
I/I |
(7,265) |
4,268,315 |
|
- |
|
| Chen Shu-Chih |
Chief Scientific Officer |
• • • |
2013-10-01 |
4 |
AS |
$5.66 |
$41,105 |
I/I |
(7,265) |
4,268,315 |
|
- |
|
| Chen Shu-Chih |
Chief Scientific Officer |
• • • |
2013-07-18 |
5 |
GD |
$0.00 |
$0 |
I/I |
105,000 |
478,543 |
|
- |
|
| Quay Steven C |
Chief Executive Officer |
• • • |
2013-07-18 |
5 |
GD |
$0.00 |
$0 |
D/D |
105,000 |
478,543 |
|
- |
|
37 Records found
|
|
Page 1 of 2 |
|
|
